Esperion Therapeutics, Inc.
Esperion Therapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on oral, once-daily, non-statin medicines for lowering LDL-C and reducing cardiovascular risk. Its core business is the commercialization of NEXLETOL and NEXLIZET in the United States, supported by ex-U.S. partnerships, supply agreements, and a preclinical pipeline built around next-generation ACLY inhibitors.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueFDA-approved oral therapies sold in the U.S. for LDL-C lowering and cardiovascular risk reduction.
Royalties and supply revenue from ex-U.S. partners commercializing licensed products.
Early-stage ACLY inhibitor research programs that may expand the product base over time.
Milestones and other contractual payments tied to collaboration agreements.
Products
Reported · share of revenue- Collaboration Revenue60.4 %
- Products39.6 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Esperion sells primarily into the U.S. cardiovascular and lipid-management market, where physicians prescribe its products for patients who need additional LDL-C lowering beyond statins or cannot reach targets on standard therapy. Outside the U.S., its customers are collaboration partners that buy API or bulk tablets and commercialize the finished products in their own territories. The end demand is driven by cardiology, primary care, and specialty lipid clinics treating patients at elevated cardiovascular risk.
Physicians prescribe NEXLETOL and NEXLIZET for patients who need oral LDL-C lowering beyond statins or ezetimibe.
Partners such as DSE, DS, and Otsuka buy API or bulk tablets and commercialize licensed products in their territories.
Cardiologists and lipid specialists use the products for patients with persistent LDL-C elevation and high CVD risk.
Primary care physicians represent a broader prescribing base for patients managed outside specialty clinics.
Strategy
Esperion’s strategy is to grow U.S. sales of NEXLETOL and NEXLIZET through label expansion, promotion, and broader market penetration. At the same time, it is using international partnerships to extend the bempedoic acid franchise without building full commercial infrastructure in every market, while also advancing preclinical ACLY inhibitors and exploring additional business development opportunities.
The company depends heavily on NEXLETOL and NEXLIZET to generate revenue and move toward profitability.
Partnerships can extend the franchise into Europe and other territories without full direct commercialization costs.
New ACLY inhibitors could reduce dependence on the current two-product franchise.
Additional products could better utilize the existing commercial organization and diversify revenue.
Geography
Esperion is commercially anchored in the United States, where NEXLETOL and NEXLIZET are sold directly. Internationally, the company relies on partners in Europe, Japan, and other territories to commercialize licensed products, while Esperion supplies API or bulk tablets and earns royalties. This structure makes U.S. execution the main revenue driver, while ex-U.S. markets provide incremental, partner-led upside with lower direct commercial spend.
Risks
Esperion is highly exposed to execution risk because it depends almost entirely on two products and must keep growing sales while funding ongoing losses and R&D. It also faces intense competition from low-cost statins, ezetimibe, PCSK9 inhibitors, and other lipid therapies, plus partner dependence, IP risk, cybersecurity risk, and potential financing constraints.
- Intense lipid-therapy competitionImpact: HighLikelihood: Medium
The market includes inexpensive generics and strong branded alternatives, which can limit uptake and pricing power.
Exposure - Financing and liquidity pressureImpact: HighLikelihood: Medium
The company has a history of operating losses and may need external capital if sales or milestones do not cover cash needs.
Exposure - Concentration in two productsImpact: HighLikelihood: Low
Most commercial value comes from bempedoic acid and the bempedoic acid/ezetimibe franchise, so any demand or safety issue would have an outsized effect.
Exposure: NEXLETOL and NEXLIZET
- Cybersecurity and IT disruptionImpact: MediumLikelihood: Medium
Commercial, clinical, and partner operations depend on internal and third-party systems that could be compromised.
Exposure: Commercialization and development programs
- Partner dependenceImpact: MediumLikelihood: Low
International revenue relies on collaborators to commercialize products, manage reimbursement, and drive sales in their territories.
Exposure
Accounting
Judgemental itemsRevenue from NEXLETOL and NEXLIZET depends on estimates for rebates, chargebacks, returns, and other deductions.
Impact: Can materially change reported product sales and quarterly comparability
API/bulk tablet revenue and royalties are recognized based on partner control and underlying sales activity.
Impact: Can create timing differences between shipments, partner sales, and reported revenue
Management uses judgment for contractual milestones and related obligations.
Impact: Affects revenue timing and other income/expense
The company disclosed losses tied to termination of a royalty interest agreement and convertible note exchange.
Impact: Can cause large one-time non-operating gains or losses
Similar listed companies
Publicly listed companies with a comparable business focus.
Exelixis, Inc
EXEL · Biological Products, (No Diagnostic Substances)
Exelixis is a U.S.-based oncology company built around cabozantinib, which it markets as CABOMETYX and COMETRIQ and uses as the core of its commercial revenue base.
Amylyx Pharmaceuticals, Inc.
AMLX · Pharmaceutical Preparations
Bicycle Therapeutics plc
BCYC · Pharmaceutical Preparations
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company built around its proprietary Bicycle platform, which is used to design short synthetic…
Lexeo Therapeutics, Inc.
LXEO · Biological Products, (No Diagnostic Substances)
Lexeo Therapeutics is a U.S.-based clinical-stage biotechnology company developing gene therapy candidates for serious cardiovascular and neuromuscular diseases.
Xencor Inc
XNCR · Pharmaceutical Preparations
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Last updated: 24/09/2026